A recent FDA advisory panel discussion has sparked concern by overstating the risks of antidepressant use in pregnancy—despite decades of research demonstrating their relative safety and the serious consequences of untreated perinatal mood and anxiety disorders. As a result, misinformation is circulating in the media and among patients, creating fear and confusion at a time when clarity and support are most needed.
What you can do:
- Affirm the evidence. Reassure patients that while no medication is entirely without risk, most SSRIs and SNRIs have a well-established safety profile during pregnancy—especially when compared to the risks of untreated depression and anxiety.
- Name the misinformation. Let patients know that even national conversations can misrepresent or oversimplify the science. Emphasize that your recommendations are grounded in peer-reviewed research and real-world clinical outcomes.
- Provide trustworthy resources. Direct patients to MotherToBaby.org for clear, evidence-based information about medication use in pregnancy and breastfeeding.
- Refer when needed. Partner with your OMHP perinatal psychiatrists and mental health professionals to offer collaborative, individualized care.
- Stay informed. For a concise summary and response to the FDA panel’s statements, see ACOG’s position: Statement on Benefit of Access to SSRIs During Pregnancy.
As trusted sources of care, OB/GYNs are uniquely positioned to offer reassurance and evidence-based guidance—helping patients navigate difficult decisions with both compassion and clarity.
Candice Norcott, PhD
Associate Professor of Psychiatry and Behavioral Neuroscience